CN114729046A - 工程化自然杀伤细胞以靶向bcma阳性肿瘤的方法 - Google Patents

工程化自然杀伤细胞以靶向bcma阳性肿瘤的方法 Download PDF

Info

Publication number
CN114729046A
CN114729046A CN202080079943.1A CN202080079943A CN114729046A CN 114729046 A CN114729046 A CN 114729046A CN 202080079943 A CN202080079943 A CN 202080079943A CN 114729046 A CN114729046 A CN 114729046A
Authority
CN
China
Prior art keywords
cells
seq
leu
ser
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080079943.1A
Other languages
English (en)
Chinese (zh)
Inventor
K·雷兹瓦尼
D·马林科斯达
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of CN114729046A publication Critical patent/CN114729046A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
CN202080079943.1A 2019-09-18 2020-09-15 工程化自然杀伤细胞以靶向bcma阳性肿瘤的方法 Pending CN114729046A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962902237P 2019-09-18 2019-09-18
US62/902,237 2019-09-18
PCT/US2020/050864 WO2021055349A1 (en) 2019-09-18 2020-09-15 A method of engineering natural killer-cells to target bcma-positive tumors

Publications (1)

Publication Number Publication Date
CN114729046A true CN114729046A (zh) 2022-07-08

Family

ID=74883668

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080079943.1A Pending CN114729046A (zh) 2019-09-18 2020-09-15 工程化自然杀伤细胞以靶向bcma阳性肿瘤的方法

Country Status (7)

Country Link
US (1) US20220370500A1 (https=)
EP (1) EP4031577A4 (https=)
JP (1) JP2022548902A (https=)
CN (1) CN114729046A (https=)
AR (1) AR119990A1 (https=)
TW (1) TW202124447A (https=)
WO (1) WO2021055349A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
KR20240021179A (ko) * 2021-05-14 2024-02-16 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 키메라 폴리펩티드 및 사용 방법
CN118265535A (zh) * 2021-10-20 2024-06-28 得克萨斯大学体系董事会 具有最佳信号传导的car构建体的工程化nk细胞
KR20240099161A (ko) 2021-10-20 2024-06-28 다케다 야쿠힌 고교 가부시키가이샤 Bcma를 표적화하는 조성물 및 이의 사용 방법
WO2023177954A1 (en) * 2022-03-18 2023-09-21 University Of Rochester Combination therapy for treatment of cancer, methods and systems of delivery thereof
JP2026512487A (ja) * 2023-04-18 2026-04-16 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｂｃｍａキメラ抗原受容体及びその使用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019075395A1 (en) * 2017-10-12 2019-04-18 Icell Gene Therapeutics, Llc COMPOUND CHIMERIC ANTIGEN RECEPTOR (CCAR) TARGETING MULTIPLE ANTIGENS AND METHODS OF USE THEREOF
CN109734814A (zh) * 2019-02-12 2019-05-10 南京卡提医学科技有限公司 具有免疫受体的工程化t细胞治疗癌症的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA033110B1 (ru) * 2012-04-11 2019-08-30 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерный рецептор антигена, направленный на антиген созревания b-клеток, кодирующая его нуклеиновая кислота, соответствующие экспрессионный вектор, клетка-хозяин, применения и способы
EA036379B1 (ru) * 2014-12-12 2020-11-02 Блубёрд Био, Инк. Химерные антигенные рецепторы к bcma
EP3283520B1 (en) * 2015-04-13 2020-05-06 Pfizer Inc Chimeric antigen receptors targeting b-cell maturation antigen
TWI833684B (zh) * 2015-06-25 2024-03-01 美商生物細胞基因治療有限公司 嵌合抗原受體（ｃａｒ）、組合物及其使用方法
WO2018195339A1 (en) * 2017-04-19 2018-10-25 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
CN109468283A (zh) * 2018-11-30 2019-03-15 北京美康基免生物科技有限公司 一种基于cd19和bcma的双重嵌合抗原受体基因修饰的免疫细胞及其应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019075395A1 (en) * 2017-10-12 2019-04-18 Icell Gene Therapeutics, Llc COMPOUND CHIMERIC ANTIGEN RECEPTOR (CCAR) TARGETING MULTIPLE ANTIGENS AND METHODS OF USE THEREOF
CN109734814A (zh) * 2019-02-12 2019-05-10 南京卡提医学科技有限公司 具有免疫受体的工程化t细胞治疗癌症的用途

Also Published As

Publication number Publication date
JP2022548902A (ja) 2022-11-22
WO2021055349A1 (en) 2021-03-25
EP4031577A4 (en) 2023-12-20
EP4031577A1 (en) 2022-07-27
US20220370500A1 (en) 2022-11-24
TW202124447A (zh) 2021-07-01
AR119990A1 (es) 2022-01-26

Similar Documents

Publication Publication Date Title
CN110719920B (zh) 蛋白质异二聚体及其用途
KR102776925B1 (ko) Flt3l-fc 융합 단백질 및 사용 방법
AU2019216689C1 (en) Treatment of cancer using humanized anti-CD19 chimeric antigen receptor
KR102658660B1 (ko) Bcma 표적 항체 및 이의 용도
CN114729046A (zh) 工程化自然杀伤细胞以靶向bcma阳性肿瘤的方法
KR102042246B1 (ko) 인터류킨-2 융합 단백질 및 이의 용도
KR102868293B1 (ko) 암 치료용 조성물 및 방법
KR102392142B1 (ko) 다량체 il-15 기반 분자
CA2719924C (en) Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
RU2741120C2 (ru) Лечение рака с использованием химерного антигенного рецептора cll-1
KR101667096B1 (ko) 돌연변이 인터루킨-2 폴리펩티드
CN107459579B (zh) 一种靶向egfr和cd47双特异性融合蛋白、制备方法及应用
KR20150041628A (ko) 인터루킨-2 융합 단백질 및 그의 용도
KR20200003367A (ko) 암 치료용 조성물 및 방법
KR20110083730A (ko) Ｃｄ37 면역치료제 병용 요법 및 이의 용도
CN111051350B (zh) 包含信号调节蛋白α的免疫缀合物
KR20190141655A (ko) 종양 형질도입용 조성물 및 방법
TW202313094A (zh) 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
CN100471872C (zh) 包含vegf受体片段的优化融合蛋白质及其医疗应用
CN113677704B (zh) Psma抗体及其应用
TW201915017A (zh) 標靶bcma的抗體及其應用
RU2799655C2 (ru) Антитело, нацеленное на всма, и его применение
KR20250111218A (ko) 혈액학적 암의 치료에 사용하기 위한 키트
HK40071848B (zh) Flt3l-fc融合蛋白和使用方法
HK40071848A (en) Flt3l-fc fusion proteins and methods of use

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220708

WD01 Invention patent application deemed withdrawn after publication